- Home
- IMAB vs GDL Comparison
IMAB vs GDL Comparison
Compare IMAB & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- GDL
- Stock Information
- Founded
- IMAB 2014
- GDL 2006
- Country
- IMAB United States
- GDL United States
- Employees
- IMAB N/A
- GDL N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- GDL Investment Managers
- Sector
- IMAB Health Care
- GDL Finance
- Exchange
- IMAB Nasdaq
- GDL Nasdaq
- Market Cap
- IMAB 83.8M
- GDL 95.2M
- IPO Year
- IMAB 2020
- GDL N/A
- Fundamental
- Price
- IMAB $1.06
- GDL $8.13
- Analyst Decision
- IMAB Strong Buy
- GDL
- Analyst Count
- IMAB 3
- GDL 0
- Target Price
- IMAB $8.00
- GDL N/A
- AVG Volume (30 Days)
- IMAB 410.6K
- GDL 11.2K
- Earning Date
- IMAB 08-28-2024
- GDL 01-01-0001
- Dividend Yield
- IMAB N/A
- GDL 6.02%
- EPS Growth
- IMAB N/A
- GDL N/A
- EPS
- IMAB N/A
- GDL N/A
- Revenue
- IMAB $3,492,091.00
- GDL N/A
- Revenue This Year
- IMAB N/A
- GDL N/A
- Revenue Next Year
- IMAB N/A
- GDL N/A
- P/E Ratio
- IMAB N/A
- GDL N/A
- Revenue Growth
- IMAB N/A
- GDL N/A
- 52 Week Low
- IMAB $0.99
- GDL $7.65
- 52 Week High
- IMAB $2.54
- GDL $8.13
- Technical
- Relative Strength Index (RSI)
- IMAB 40.43
- GDL 49.42
- Support Level
- IMAB $1.02
- GDL $8.09
- Resistance Level
- IMAB $1.12
- GDL $8.21
- Average True Range (ATR)
- IMAB 0.08
- GDL 0.05
- MACD
- IMAB -0.01
- GDL -0.00
- Stochastic Oscillator
- IMAB 20.00
- GDL 29.75
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.